Resources

Client Alerts, News Articles, Blog Posts, & Multimedia

Everything you need to know about BMD and the industry.

Changes to Physician Assistant Statutes in Florida

Client Alert

In the last year, there have been many changes to the scope of practice and collaboration/supervision requirements for advanced practice providers such as APRNs and physician assistants in the state of Florida.  In a previous Client Alert we discussed House Bill 607, which expanded the autonomous practice of APRNs providing primary care services in Florida.

This Client Alert focuses on Florida House Bill 431 (the “Bill”), which went into effect on July 1, 2021 and amended Florida Statutes 458.347 and 459.022. The Bill essentially gives Florida PAs more autonomy in certain aspects of their practice, and changes the number of PAs that physicians are permitted to supervise from four (4) to ten (10).

The Florida Board of Medicine published the comprehensive list of all of the changes made, and among those, PAs are no longer required to notify patients that they have the right to see a physician before prescribing or dispensing prescriptions, and they are able to authenticate any document that may also be authenticated by physicians, with the exception of physician certifications (which includes, but is not limited to, death certificates, school physical exams, and medical examinations for workers’ compensation claims).

Additionally, PAs are no longer required to notify the Department of Health in writing when any changes are made to their supervising physician or within thirty (30) days of employment, and are permitted to supervise medical assistants.

As for changes in prescribing, PAs no longer need to include a prescribing number on prescriptions, but instead must include their name, address, and phone number, along with the name of each of their supervising physicians. Additionally, a formulary that lists prescriptions PAs are not allowed to prescribe will be published, and PAs can now prescribe 14-day supplies of Schedule II psychotropic drugs to minors, provided they are supervised by a pediatrician, family practice physician, internal medicine physician, or psychiatrist.

The Board of Medicine also noted the following changes from the Bill:

  • Amends provisions related to program approval for the education and training of PAs and allows trainees to perform medical services rendered within the scope of an approved program;
  • Amends the licensure requirements for PAs based on the date a PA graduated from an approved program as defined in the bill by specifying which PA education and training programs are approved for PA licensure;
  • Authorizes a PA to satisfy the continuing education requirement on controlled substance prescribing through a designated course; and
  • Removes the requirement that PA licensure applicants seeking prescribing authority provide course transcripts.

If you have any questions about any of the specific changes or additions to Florida Statutes 458.347 and 459.022, and how they are applicable to you and your practice, please contact Amanda Waesch at alwaesch@bmdllc.com.


CMS Releases CY 2026 Medicare Physician Fee Schedule Final Rule with Key Payment and Telehealth Updates

CMS issued the CY 2026 Medicare Physician Fee Schedule Final Rule on October 31, 2025, with changes effective January 1, 2026. The Final Rule includes increases to the conversion factor, a new efficiency adjustment, updates to practice expense methodology, permanent telehealth policy changes, revised payment for skin substitutes, expanded rules for Part B drugs and biologicals, enhanced policies for Rural Health Clinics and Federally Qualified Health Centers, and new care management and behavioral health services.

Ohio Department of Medicaid Updates: Key Changes to Physician Reimbursement Rates in Early Parenthood

The Ohio Department of Medicaid has proposed amending Ohio Administrative Code Rule related to covered Medicaid reimbursements for physicians. Beginning on January 1, 2026, they are proposing an increase to rates for prenatal care, childbirth, and infant care and provider visits.

Name, Image, and Likeness Agreements in Healthcare

For example, some healthcare providers have begun to utilize "Name, Image, and Likeness" agreements to promote the brand they have created through their healthcare practice.  We have seen the most healthcare NIL activity with longevity and wellness providers, as well as orthopedics.

Compounding GLP-1 Drugs - Recent Updates

Recent guidance from the Ohio Board of Pharmacy (“BOP”) indicates that providers should generally use the FDA approved GLP-1 drug, rather than a non-FDA approved compounded version of the medication. Importantly, if a GLP-1 drug is commercially available, it cannot be copied through compounding. Currently, compounded copies of Tirzepatide and Semaglutide are not permitted.

Top Compliance Risks for Ohio Med-Spas in 2025

The Ohio Board of Pharmacy has increased inspections of med-spas holding Terminal Distributor of Dangerous Drugs (TDDD) licenses, with many facing enforcement actions in 2025. Common issues include purchasing from unlicensed distributors, improper drug storage, inadequate recordkeeping, and insufficient prescriber oversight. Understanding these risks and maintaining compliance can help protect your practice from penalties and license suspension.